Inbrain Neuroelectronics

Executive Summary

Inbrain Neuroelectronics, a Spanish neurotechnology company founded in 2019, is developing next-generation brain-computer interfaces (BCIs) using patented graphene-based technology. Its flexible, high-resolution neural implants aim to decode and modulate neural networks, offering a novel therapeutic approach for severe neurological disorders. The company's initial focus is on Parkinson's disease, where it seeks to provide more precise and less invasive neuromodulation compared to traditional deep brain stimulation. By leveraging graphene's superior conductivity and biocompatibility, Inbrain's implants could enable real-time, closed-loop therapy, potentially improving patient outcomes and expanding the addressable market for neurostimulation devices. The company is currently in the preclinical stage, with no disclosed funding rounds or valuation. Its potential hinges on successful first-in-human trials, which are expected within the next 12–18 months. Key risks include technical hurdles in scaling graphene manufacturing, regulatory approval timelines, and competition from established neurostimulation players. However, Inbrain's unique material platform and strong IP position could attract strategic partnerships or venture capital. The near-term pipeline focuses on completing preclinical validation and initiating human studies for Parkinson's, with subsequent expansion into other conditions such as epilepsy and depression.

Upcoming Catalysts (preview)

• H2 2027First-in-human study initiation for Parkinson's BCI30% success
• H1 2027Series A funding round50% success
• H1 2027Breakthrough Device Designation from FDA40% success